{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T20:11:57Z","timestamp":1780344717598,"version":"3.54.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002560","name":"Soonchunhyang University","doi-asserted-by":"publisher","award":["SCH-20230328"],"award-info":[{"award-number":["SCH-20230328"]}],"id":[{"id":"10.13039\/501100002560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2023-NR076438 (NRF-2023R1A2C1003486)"],"award-info":[{"award-number":["RS-2023-NR076438 (NRF-2023R1A2C1003486)"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p><jats:italic>Candida auris<\/jats:italic> has emerged as a critical nosocomial pathogen that particularly affects immunocompromised and critically ill patients in intensive care units, and it is associated with high mortality. The robust biofilm-forming ability and inherent fluconazole resistance of <jats:italic>C. auris<\/jats:italic> pose considerable treatment challenges. Consequently, novel therapeutic strategies are urgently needed to treat fluconazole-resistant <jats:italic>C. auris<\/jats:italic> (FRCA). This study investigated the antifungal effect of the combination of fluconazole with fingolimod against FRCA. The antifungal activity of fingolimod and resistance of <jats:italic>C. auris<\/jats:italic> to fluconazole were assessed using a minimum inhibitory concentration assay, and their interaction was evaluated through a checkerboard synergy assay. The combination treatment effectively inhibited early biofilm formation and eradicated mature biofilms, as demonstrated by the biofilm inhibition concentration and biofilm eradication concentration assays, respectively. The XTT reduction assay revealed a marked reduction in the metabolic activity of <jats:italic>C. auris<\/jats:italic>, which was further corroborated by confocal laser-scanning microscopy. Quantitative polymerase chain reaction revealed the downregulation of key virulence-associated genes, including <jats:italic>ERG11<\/jats:italic> (azole resistance), <jats:italic>CDR1<\/jats:italic> (efflux pump), and <jats:italic>KRE6<\/jats:italic> (extracellular matrix). Collectively, these findings indicate that the combination of fingolimod and fluconazole inhibits biofilm formation, fungal metabolic activity, and virulence-related gene expression. This study suggests that fingolimod could serve as an adjuvant to improve the efficacy of fluconazole against FRCA.<\/jats:p>","DOI":"10.3389\/fcimb.2025.1631780","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:30:16Z","timestamp":1758605416000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Fingolimod potentiates the antifungal activity of fluconazole against fluconazole-resistant Candida auris"],"prefix":"10.3389","volume":"15","author":[{"given":"Ji-Hui","family":"Bae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Bin","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nrneurol.2010.76","article-title":"Fingolimod is a potential novel therapy for multiple sclerosis","volume":"6","author":"Aktas","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3201\/eid2605.191588","article-title":"Clinical outcomes of patients treated for Candida auris infections in a multisite health system, Illinois, USA","volume":"26","author":"Arensman","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1038\/s41598-019-41513-6","article-title":"Gene duplication associated with increased fluconazole tolerance in Candida auris cells of advanced generational age","volume":"9","author":"Bhattacharya","year":"2019","journal-title":"Sci. Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/1756285612450936","article-title":"Current and emerging therapies in multiple sclerosis: a systematic review","volume":"5","author":"Castro-Borrero","year":"2012","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02788","article-title":"Review on antifungal resistance mechanisms in the emerging pathogen Candida auris","volume":"10","author":"Chaabane","year":"2019","journal-title":"Front. Microbiol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/jof9090913","article-title":"An overview on Candida auris in healthcare settings","volume":"9","author":"Cristina","year":"2023","journal-title":"J. Fungi"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12050927","article-title":"Candida auris outbreaks: current status and future perspectives","volume":"12","author":"De Gaetano","year":"2024","journal-title":"Microorganisms"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e1008921","DOI":"10.1371\/journal.ppat.1008921","article-title":"Candida auris: Epidemiology, biology, antifungal resistance, and virulence","volume":"16","author":"Du","year":"2020","journal-title":"PloS Pathog."},{"key":"B9","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.mimet.2011.05.019","article-title":"Biofilm formation by five species of Candida on three clinical materials","volume":"86","author":"Estivill","year":"2011","journal-title":"J. Microbiol. Methods"},{"key":"B10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12929-023-00926-2","article-title":"Diagnosis of invasive fungal infections: challenges and recent developments","volume":"30","author":"Fang","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8111834","article-title":"Screening of FDA-approved drugs using a 384-well plate-based biofilm platform: The case of fingolimod","volume":"8","author":"Gilbert-Girard","year":"2020","journal-title":"Microorganisms"},{"key":"B12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40588-020-00143-7","article-title":"Candida auris infection and biofilm formation: going beyond the surface","volume":"7","author":"Horton","year":"2020","journal-title":"Curr. Clin. Microbiol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00029-17","article-title":"Candida auris: a review of the literature","volume":"31","author":"Jeffery-Smith","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12866-016-0728-1","article-title":"The calcineruin inhibitor cyclosporine a synergistically enhances the susceptibility of Candida albicans biofilms to fluconazole by multiple mechanisms","volume":"16","author":"Jia","year":"2016","journal-title":"BMC Microbiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jtcme.2024.06.005","article-title":"Potent anti-biofilm properties of plumbagin against fluconazole-resistant Candida auris","volume":"15","author":"Jin","year":"2025","journal-title":"J. Tradit. Complement. Med."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11081043","article-title":"Fingolimod promotes antibacterial effect of doripenem against carbapenem-resistant Escherichia coli","volume":"11","author":"Jin","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00334-18","article-title":"Transcriptome assembly and profiling of Candida auris reveals novel insights into biofilm-mediated resistance","volume":"3","author":"Kean","year":"2018","journal-title":"mSphere"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e00458","DOI":"10.1128\/mSphere.00458-19","article-title":"Combined antifungal resistance and biofilm tolerance: the global threat of Candida auris","volume":"4","author":"Kean","year":"2019","journal-title":"mSphere"},{"key":"B19","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1006\/bbrc.1995.1272","article-title":"Mode of action and resistance to azole antifungals associated with the formation of 14\u03b1-methylergosta-8, 24 (28)-dien-3\u03b2, 6\u03b1-diol","volume":"207","author":"Kelly","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10020161","article-title":"Synergistic activity of equol and meropenem against carbapenem-resistant Escherichia coli","volume":"10","author":"Kim","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/jam.14870","article-title":"Antifungal and anti-biofilm effects of 6-shogaol against Candida auris","volume":"130","author":"Kim","year":"2021","journal-title":"J. Appl. Microbiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s12088-022-01020-1","article-title":"Anti-bacterial and anti-biofilm effects of equol on yersinia enterocolitica","volume":"62","author":"Kim","year":"2022","journal-title":"Indian J. Microbiol."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myae042","article-title":"Candida auris\u2014A systematic review to inform the world health organization fungal priority pathogens list","volume":"62","author":"Kim","year":"2024","journal-title":"Med. Mycol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.anaerobe.2019.04.001","article-title":"Anti-biofilm and antimicrobial effects of zerumbone against Bacteroides fragilis","volume":"57","author":"Kim","year":"2019","journal-title":"Anaerobe"},{"key":"B25","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1099\/mic.0.000930","article-title":"Anti-biofilm and anti-virulence effects of zerumbone against Acinetobacter baumannii","volume":"166","author":"Kim","year":"2020","journal-title":"Microbiology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.fgb.2019.103243","article-title":"Candida auris and multidrug resistance: defining the new normal","volume":"131","author":"Lockhart","year":"2019","journal-title":"Fungal Genet. Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/jof910095","article-title":"Biofilm formation in medically important Candida species","volume":"9","author":"Malinovsk\u00e1","year":"2023","journal-title":"J. Fungi"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1128\/aac.44.9.2373-2381.2000","article-title":"Potent\u00a0synergism of the combination of fluconazole and cyclosporine in Candida albicans","volume":"44","author":"Marchetti","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/5584_2016_6","article-title":"The extracellular matrix of fungal biofilms","volume":"931","author":"Mitchell","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e0278488","DOI":"10.1371\/journal.pone.0278488","article-title":"Immunomodulatory drug fingolimod (FTY720) restricts the growth of opportunistic yeast Candida albicans in vitro and in a mouse candidiasis model","volume":"17","author":"Najarzadegan","year":"2022","journal-title":"PloS One"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13070621","article-title":"FTY720 reduces the biomass of biofilms in pseudomonas aeruginosa in a dose-dependent manner","volume":"13","author":"Niazy","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2018.26","article-title":"Invasive candidiasis","volume":"4","author":"Pappas","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2017.00011","article-title":"Oral multiple sclerosis drugs inhibit the in vitro growth of epsilon toxin producing gut bacterium, Clostridium perfringens","volume":"7","author":"Rumah","year":"2017","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2022.102208","article-title":"The molecular and genetic basis of antifungal resistance in the emerging fungal pathogen Candida auris","volume":"70","author":"Rybak","year":"2022","journal-title":"Curr. Opin. Microbiol."},{"key":"B35","article-title":"WHO fungal priority pathogens list to guide research, development and public health action","author":"Sati","year":"2022"},{"key":"B36","doi-asserted-by":"crossref","unstructured":"Shang\n              Y.\n            \n            \n              Huang\n              Y.\n            \n            \n              Meng\n              Q.\n            \n            \n              Yu\n              Z.\n            \n            \n              Wen\n              Z.\n            \n            \n              Yu\n              F.\n            \n          \n          Targeting Phospholipids: Fingolimod\u2019s Antibacterial Mechanism Against \n          \n          2024","DOI":"10.21203\/rs.3.rs-5223352\/v1"},{"key":"B37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jhin.2019.06.006","article-title":"Candida auris exhibits resilient biofilm characteristics in vitro: implications for environmental persistence","volume":"103","author":"Short","year":"2019","journal-title":"J. Hosp. Infect."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12010087","article-title":"Antimicrobial treatment of Staphylococcus aureus biofilms","volume":"12","author":"Tuon","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.627917","article-title":"Fingolimod potentiates the antifungal activity of amphotericin B","volume":"11","author":"Wei","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s00284-016-1081-1","article-title":"Crystal violet and XTT assays on Staphylococcus aureus biofilm quantification","volume":"73","author":"Xu","year":"2016","journal-title":"Curr. Microbiol."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.680382","article-title":"Effects of Hsp90 inhibitor ganetespib on inhibition of azole-resistant","volume":"12","author":"Yuan","year":"2021","journal-title":"Candida albicans. Front. Microbiol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1631780\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:30:18Z","timestamp":1758605418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1631780\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":41,"alternative-id":["10.3389\/fcimb.2025.1631780"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1631780","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"article-number":"1631780"}}